Could the Keto Diet Help Treat Anorexia, Schizophrenia and Depression?

Why It Matters

If confirmed, keto could become a low‑cost metabolic adjunct for psychiatric treatment, expanding therapeutic options beyond drugs and addressing the metabolic underpinnings of mental illness.

Key Takeaways

• Small trials show keto improves depression, bipolar, schizophrenia symptoms
• 88‑person RCT found modest benefit for treatment‑resistant depression
• Pilot study reports keto reduces anorexia nervosa eating‑disorder thoughts
• Researchers link mental illness to metabolic dysfunction and brain energy deficits
• Ongoing RCTs aim to confirm keto’s efficacy and safety for psychiatry

Pulse Analysis

The brain’s voracious appetite for energy—using roughly 20% of the body’s calories despite representing only 2% of its mass—has long made metabolism a focal point for neurological research. Historically, the ketogenic diet emerged in the 1920s as a seizure‑reducing therapy for children with refractory epilepsy, leveraging the brain’s ability to switch from glucose to ketone bodies. Modern scientists now view many psychiatric conditions through a metabolic lens, noting that disruptions in glucose utilization and mitochondrial health often accompany depression, bipolar disorder, and schizophrenia.

New clinical data are sharpening that hypothesis. An 88‑participant randomized controlled trial published early this year demonstrated a modest but statistically significant reduction in depressive scores among patients adhering to a strict keto regimen, even as they continued standard antidepressant therapy. Parallel pilot studies have observed symptom attenuation in bipolar and schizophrenia cohorts, while a recent small‑scale trial reported that individuals with anorexia nervosa experienced fewer restrictive thoughts without losing weight. Researchers propose that ketosis stabilizes the excitatory‑inhibitory neurotransmitter balance (glutamate/GABA), enhances mitochondrial efficiency, and dampens systemic inflammation—mechanisms that collectively could normalize brain circuitry implicated in mood and psychotic disorders.

The potential ramifications are sizable. Should ongoing multi‑site RCTs confirm efficacy and delineate safety parameters, clinicians might adopt a metabolic adjunct that is inexpensive, widely accessible, and synergistic with existing pharmacotherapies. However, experts caution that keto can interact unpredictably with psychiatric medications and may trigger manic episodes in susceptible individuals, underscoring the need for medical supervision. This emerging paradigm reflects a broader shift toward treating mental illness as a systemic, metabolic disorder, aligning dietary interventions with drug developments such as GLP‑1 agonists that target both weight and brain health.